Previous Close | 3.3700 |
Open | 3.4500 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 1200 |
Day's Range | 3.4000 - 3.4990 |
52 Week Range | 2.7500 - 32.0000 |
Volume | |
Avg. Volume | 20,994 |
Market Cap | 12.634M |
Beta (5Y Monthly) | 77.95 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -17.7440 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for BRTX
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the first patient has been enrolled in the Company’s Phase 2 clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived mesenchymal stem cell targeting chronic lumbar disc disease (cLDD). T
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Center for Clinical Research, which is located in North Carolina, is BioRestorative’s second clinical trial contract executed. BioRestorative’s Phase
BioRestorative Therapies Inc (NASDAQ: BRTX) has selected the Center for Clinical Research in North Carolina as the company's second contract for its Phase 2 trial targeting chronic lumbar disc disease (cLDD). BioRestorative develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. What Happened: The Phase 2 trial will evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the company's autologous investigational stem cell